CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05544968
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:03.322292+00:00
Published At: 2026-04-03T00:00:00+00:00
Record Updated At: 2026-04-03
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Hodgkin Disease", "CD30-Positive Diffuse Large B-Cell Lymphoma", "CD30+ Anaplastic Large Cell Lymphoma", "CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma", "CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma", "Leukemia", "Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-03"
protocolSection.identificationModule.nctId: "NCT05544968"
protocolSection.identificationModule.officialTitle: "A Phase I Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-Armed Anti-CD3-Activated Autologous T-Cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.